Clinical trial
S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in…
NCT00005834 · SWOG Cancer Research Network, Other · Terminated
Key facts
| NCT number | NCT00005834 |
|---|---|
| Title | S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma |
| Official title | A Phase III Trial of Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin (DCEP) and G-CSF With or Without Thalidomide (NSC #66847) as Salvage Therapy for Patients With Refractory Multiple Myeloma |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, cisplatin, cyclophosphamide, dexamethasone, etoposide, thalidomide |
| Enrollment | 19 |
| Start date | Apr 1, 2000 |
| Primary completion | Nov 1, 2003 |
| Completion | Nov 1, 2007 |
| First posted | Mar 16, 2004 |
| Last update posted | Mar 6, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: